CStone Pharmaceuticals
HKEX:2616

Watchlist Manager
CStone Pharmaceuticals Logo
CStone Pharmaceuticals
HKEX:2616
Watchlist
Price: 4.23 HKD -2.98% Market Closed
Market Cap: 5.8B HKD

Intrinsic Value

CStone Pharmaceuticals's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one CStone Pharmaceuticals stock under the Base Case scenario is 3.47 HKD. Compared to the current market price of 4.23 HKD, CStone Pharmaceuticals is Overvalued by 18%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
3.47 HKD
Overvaluation 18%
Intrinsic Value
Price
Base Case Scenario

Valuation History
CStone Pharmaceuticals

Valuation History Unavailable

Historical valuation for CStone Pharmaceuticals cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%
Compare CStone Pharmaceuticals to

Fundamental Analysis

Company Overview
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about CStone Pharmaceuticals?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about CStone Pharmaceuticals
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
CStone Pharmaceuticals

Current Assets 1.1B
Cash & Short-Term Investments 672.9m
Receivables 83.9m
Other Current Assets 333m
Non-Current Assets 303.6m
Long-Term Investments 9m
PP&E 130.5m
Intangibles 161.4m
Other Non-Current Assets 2.6m
Efficiency

Free Cash Flow Analysis
CStone Pharmaceuticals

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
CStone Pharmaceuticals

Revenue
407.2m CNY
Cost of Revenue
-167.1m CNY
Gross Profit
240.2m CNY
Operating Expenses
-322.1m CNY
Operating Income
-81.9m CNY
Other Expenses
-9.3m CNY
Net Income
-91.2m CNY
Fundamental Scores

Profitability Score
Profitability Due Diligence

CStone Pharmaceuticals's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

28/100
Profitability
Score

CStone Pharmaceuticals's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

CStone Pharmaceuticals's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
37/100
Solvency
Score

CStone Pharmaceuticals's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
CStone Pharmaceuticals

Wall Street analysts forecast CStone Pharmaceuticals stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CStone Pharmaceuticals is 2.83 HKD with a low forecast of 2.8 HKD and a high forecast of 2.91 HKD.

Lowest
Price Target
2.8 HKD
34% Downside
Average
Price Target
2.83 HKD
33% Downside
Highest
Price Target
2.91 HKD
31% Downside
View Analyst Estimates
View Analyst Estimates

Dividends

CStone Pharmaceuticals
does not pay dividends
Shareholder Yield

Current shareholder yield for CStone Pharmaceuticals is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one CStone Pharmaceuticals stock?

The intrinsic value of one CStone Pharmaceuticals stock under the Base Case scenario is 3.47 HKD.

Is CStone Pharmaceuticals stock undervalued or overvalued?

Compared to the current market price of 4.23 HKD, CStone Pharmaceuticals is Overvalued by 18%.

Back to Top